Pharmacokinetic Bioequivalence Study of Nebcinal® 150mg/3ml Administered by Aeroneb® Idehaler® Versus Tobi® 300mg/5ml Administered by Pari LC Plus® /Pulmoaid® in Patients With Cystic Fibrosis (RM/NEB-03-10)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01337219
Recruitment Status : Unknown
Verified February 2011 by Erempharma.
Recruitment status was:  Recruiting
First Posted : April 18, 2011
Last Update Posted : April 18, 2011
University of Lyon
Epidemiologie Pharmacologie Investigation Clinique Information medicale Mere Enfant (EPICIME)
Clininfo S.A.
Hospices Civils de Lyon
Information provided by:

No Study Results Posted on for this Study
  Recruitment Status : Unknown
  Estimated Primary Completion Date : September 2011
  Study Completion Date : No date given